Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 22 November 2024

Overview

The Therapeutic Goods Act 1989 was enacted by the Commonwealth Parliament to regulate the quality, safety, and efficacy of therapeutic goods, including medicines, medical devices, and blood products. This legislation was introduced to address the need for stringent control and oversight of therapeutic goods to protect public health and ensure that products available in the Australian market meet established standards. The Act provides the framework for the regulation of therapeutic goods, including the licensing of manufacturers. The policy objective of the Act is to ensure that therapeutic goods available in Australia are of acceptable quality and are safe for consumers. The recent publication of the list of manufacturers granted a licence for the manufacture of therapeutic goods under Section 38 of the Act, signed by Katherine Clark, Delegate of the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, continues to uphold these objectives by providing transparency and accountability in the manufacturing processes of licensed companies.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities engaged in the manufacture, supply, importation, or distribution of therapeutic goods in Australia. This legislation, overseen by the Department of Health and Aged Care, specifically targets the manufacturing of therapeutic goods and mandates that any entity involved in this activity must hold a licence. The named entities, including Baxter Healthcare Pty Ltd, Mainfreight Distribution Pty Ltd, Australian Red Cross Lifeblood, and DHL Supply Chain Australia Pty Limited, are subject to this requirement, which ensures the safety and quality of therapeutic goods available to consumers. The Act's jurisdictional reach extends across the Commonwealth of Australia, and its application is comprehensive, covering all therapeutic goods irrespective of their form or intended use. However, certain therapeutic goods such as blood and blood components may be subject to exclusions or specific regulations under subordinate instruments, which can extend or restrict the application of the Act. This regulatory framework is designed to maintain high standards in the therapeutic goods sector, safeguarding public health.

Key Provisions

The Therapeutic Goods Act 1989 outlines various provisions relating to the regulation of therapeutic goods in Australia. Section 38 of the Act (Section 38) permits the Secretary to grant licences to manufacturers of therapeutic goods, ensuring that these products meet safety, quality, and efficacy standards. This section is particularly important as it empowers the Secretary to officially recognise and approve entities that meet the stringent requirements for manufacturing therapeutic goods. This recognition is crucial in maintaining public trust and ensuring that only compliant products are available for consumer use. The grant of a licence under Section 38 imposes specific obligations on the licence holders. These entities are required to adhere to Good Manufacturing Practice (GMP) standards, maintain accurate records, and ensure that their products are manufactured in a manner that safeguards public health. This includes rigorous quality control measures, regular audits, and compliance with all relevant regulations and guidelines set forth by the Therapeutic Goods Administration (TGA). Licence holders must also report any adverse events or product defects to the TGA promptly. Breaches of the obligations and requirements under the Therapeutic Goods Act 1989 can result in significant consequences. The Act stipulates various offences, including the unauthorised manufacture of therapeutic goods, which can be prosecuted under both civil and criminal law. For example, Section 33DA of the Act outlines that knowingly making a false statement in an application for a licence or permit is a criminal offence, punishable by a maximum penalty of $220,000 for individuals and $1,100,000 for bodies corporate, as per Section 33DC. Additionally, Section 33DB highlights that the unauthorised manufacture of therapeutic goods is an offence that can attract a maximum penalty of $1,100,000 for individuals and $5,500,000 for bodies corporate. These penalties underscore the seriousness with which the Act treats non-compliance and the potential ramifications for entities found in breach of its provisions.